Sgd Pharma
Sgd Pharma, headquartered in France, is a leading player in the pharmaceutical packaging industry, specialising in the design and manufacture of glass primary packaging solutions. Founded in 2002, the company has established a strong presence across Europe, Asia, and the Americas, catering to the diverse needs of the pharmaceutical and biotechnology sectors. With a commitment to quality and innovation, Sgd Pharma offers a comprehensive range of products, including vials, ampoules, and syringes, all designed to meet stringent regulatory standards. Their unique approach combines advanced manufacturing techniques with a focus on sustainability, positioning them as a trusted partner for global pharmaceutical companies. Notably, Sgd Pharma has achieved significant milestones in product development and market expansion, solidifying its reputation as a key player in the industry.
DitchCarbon Score
How does Sgd Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Rubber and Plastic Products industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Sgd Pharma's score of 32 is higher than 97% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Sgd Pharma's reported carbon emissions
In 2023, SGD Pharma reported total carbon emissions of approximately 403,316,000 kg CO2e, comprising 203,584,000 kg CO2e from Scope 1, 199,732,000 kg CO2e from Scope 2, and 10,000,000 kg CO2e from Scope 3 emissions. This marks a significant commitment to transparency in their emissions reporting. Over the years, SGD Pharma has demonstrated a consistent approach to managing its carbon footprint. In 2022, the company recorded total emissions of about 436,649,000 kg CO2e, with Scope 1 emissions at 217,057,000 kg CO2e and Scope 2 emissions at 218,590,000 kg CO2e. The trend shows a gradual reduction in emissions from 2020, where total emissions were approximately 436,003,000 kg CO2e, indicating ongoing efforts to improve sustainability. SGD Pharma has committed to near-term emissions reduction targets, although they have not set a net-zero target as of now. Their commitment to reducing emissions aligns with industry standards, reflecting a proactive stance in the Containers and Packaging sector. The company continues to focus on enhancing its sustainability practices while addressing its carbon emissions comprehensively.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Scope 1 | 65,567,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 9,640,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | 1,899,000 | - | - | - | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Sgd Pharma is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
